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Objective: In a prospective, randomized study, postoperatively prolonged 
antibiotic prophylaxis is evaluated in a high-risk group of patients under- 
going cardiac operations. These patients had postoperative low cardiac 
output necessitating inotropic support and intraaortic balloon pumping. 
Methods: Between January 1991 and 1994, 53 patients were enrolled in the 
study (42 men, mean age 65 years). All patients received the usual 
perioperative (24 hours) cefazolin prophylaxis. In the study group (n = 28) 
a prolonged regimen of prophylaxis with ticarcillin/clavulanate was per- 
formed for 2 days and vancomycin was added in a low dose until removal 
of the intraaortic balloon pump. The control group (n = 25) did not receive 
a prolonged regimen of prophylaxis. Follow-up ended at hospital discharge. 
Results: Early mortality was 7 of 28 patients (25%) in the prophylaxis group 
and 8 of 25 patients (32%) in the control group (p = 0.397). Defined 
infections (pneumonia, n = 22; sepsis, n = 8; deep sternal wound infection, 
n = 2) occurred in 50% of the study group and 68% of the control group 
(p = 0.265). In all patients with septicemia, only coagulase-negative 
staphylococci ould be isolated from the bloodstream (5 patients in the 
prophylaxis group vs 3 in the control group). Infectious parameters were 
controlled aily and did not differ significantly between groups. A total of 
1158 bacteriologic tests were performed (blood cultures, n = 389; intravas- 
cular catheters, n = 208; bronchial aspirates, n = 411; intraaortic balloon 
pumps, n = 42; wound secretions, n = 108) showing bacterial growth in 322 
(28%) without a significant difference between the groups. In the prophy- 
laxis group, 13 intravascular catheters and intraaortic balloon pumps 
showed bacterial growth versus 11 in the control group. No side effects were 
seen. Conclusion: In a high-risk group of patients undergoing cardiac 
operations, infectious outcome could not be effectively influenced by an 
additional and prolonged postoperative prophylaxis regimen with low-dose 
vancomycin and ticarcillin/clavulanat e. Low-dose vancomycin did not re- 
duce the rate of infections or colonizations of intravascular catheters with 
gram-positive organisms. (J Thorac Cardiovasc Surg 1997;114:162-8) 
A ntibiotic prophylaxis has been performed rou- tinely in cardiac surgery since Geraci, Dale, and 
McGoon 1 in 1963 reported about a 10% incidence 
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of prosthetic valve endocarditis with staphylococci. 
In placebo groups of prospective, randomized stud- 
ies, wound infection rates even ranged from 9.1% to 
54.5%. 2 In the meantime, the benefit of a short 
(mostly 24 hours) perioperative prophylaxis regimen 
has been confirmed by several authors. 2-s Long-term 
prophylaxis could not be demonstrated 6-9 to be 
efficacious in patients who were undergoing cardiac 
operations and who did not have high risk factors. In 
long-term prophylaxis, principal target organisms 
have been coagulase-negative staphylococci (CNS) 
associated with nosocomial infections and endocar- 
ditis. 
In a prospective, randomized study we have eval- 
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uated postoperatively prolonged antibiotic prophy- 
laxis in a high-risk group of patients undergoing 
cardiac operations. The working hypothesis was that 
prolonged administration of antibiotics can prevent 
or reduce infectious complications. Currently the 
l iterature contains no reports about reduction of 
nosocomial  infections by postoperatively extended 
application of antibiotics in such a subgroup of 
patients. 
Patients and methods 
Patients with severe heart failure who could not be 
weaned from cardiopulmonary b pass without intraaortic 
balloon pumping (IABP) were included in the study. 
Immediately after the operation the patients receiving 
IABP support were randomized into two groups accord- 
ing to a randomization list. All patients received the usual 
perioperative intravenous antibiotic prophylaxis with 3 gm 
of cefazolin in 24 hours. The first dose of 1 gm was given 
at induction of anesthesia, the second dose (1 gm) after 8 
hours, and the third dose (1 gin) after another interval of 
8 hours. Patients of the study group (prophylaxis group) 
were subjected to a prolonged regimen of antibiotic 
prophylaxis that started after completion of the cefazolin 
prophylaxis. The protocol was as follows: Ticarcillin/ 
clavulanate (Timenten, SmithKline Beecham AG) was 
administered as a short-term intravenous infusion. The 
dose of 5.2 gm was administered every 8 hours for 2 days. 
Additionally, vancomycin was administered in a low intra- 
venous dosage of 500 mg every 12 hours until removal of 
the IABP. Patients in the control group received the 
normal perioperative cefazolin prophylaxis for 24 hours 
but not the prolonged prophylaxis. Patients with preexist- 
ing infections necessitating antibiotic treatment and pa- 
tients with an allergy to betalactam antibiotics or vanco- 
mycin were excluded from the study. 
Definitions. All patients were evaluated aily for infec- 
tion until the end of the hospitalization. The following 
infections were defined according to the definitions of the 
Centers for Disease Control and Prevention1°: Wound 
infection indicates incisional wound infections involving 
the skin, subcutaneous tissue, or muscle above the fascial 
layer with purulent drainage from the incision or bacterial 
growth from wounds that are primarily closed. Deep 
surgical wound infections involve tissues beneath the 
fascial layer with purulent drainage from deeply placed 
drains, with spontaneous dehiscences or purulent and 
culture-positive secretion after surgical opening. An ab- 
scess or other evidence of infection can be seen on direct 
examination, during the operation, or by histopathologic 
examination. Pneumonia is defined as purulent and cul- 
ture-positive bronchial or tracheal secretion (obtained by 
transtracheal spiration, bronchial brushing, or biopsy) in 
the presence of clinical and radiologic signs suggestive of 
pneumonia. Two types of bloodstream infection were iden- 
tified. Primary bloodstream infection includes isolation of a 
pathogen in a blood culture and clinical sepsis. If an 
organism is related to a nosocomial infection at another 
site, the bloodstream infection is classified as secondary. 
Catheter infection (more than five colonies on the agar 
plate rolled over by the tip of the catheter) is distinguished 
from contamination by means of a semiquantitative tech- 
nique. 11 
Bacteriology/laboratory findings. The following exam- 
inations were routinely performed in all patients: (1) 
bacteriologic examination of a wound swab, with an open 
thorax at each change of wound dressing; (2) bacteriologic 
examination of all intravascular catheters and the IABP 
catheter; (3) bacteriologic examination of tracheal secre- 
tions at least once per day until extubation (Gram stain/ 
culture); (4) three blood cultures (aerobic and anaerobic) 
before the start of prolonged prophylaxis; (5) three blood 
cultures when the body temperature was more than 
38.5 ° C. 
Daily laboratory studies included the following: hemo- 
globin concentration, hematocrit value, white blood cell 
count, platelet count, phosphate, C-reactive protein, cre- 
atinine, creatinine clearance on the first postoperative 
day, and daily body temperature. Chest roentgenograms 
were obtained daily during the patients' stay in the 
intensive care unit. 
Between January 1991 and January 1994, cardiac oper- 
ations with the heart-lung machine were performed in 
2152 adult patients at the Clinic for Cardiovascular Sur- 
gery of the University Hospital and the City Hospital 
Triemli of Ztirich. O f  this series, 53 (2.4%) consecutive 
patients (42 men) were included in the study, which was 
approved by the ethics committee and the institutional 
review board of the hospital. Informed consent was ob- 
tained from the patients or their legal representatives. All 
patients had severely reduced left ventricular function 
with low cardiac output syndrome and with the need for 
inotropic support and IABP to be weaned from cardio- 
pulmonary bypass. The study group (receiving additional 
vancomycin/ticarcillin prophylaxis) comprised 28 patients 
(25 men) and the control group (receiving only the short 
perioperative c fazolin prophylaxis), 25 patients (17 men). 
The difference in sex between the two groups approached 
statistical significance (p = 0.058). Mean age was 64.7 
years (SD* 9.5 years, minimum 35 years, maximum 83 
years) and was not significantly different in the two groups 
(p = 0.605). The following operations were performed: 
coronary artery bypass grafting (CABG), 33; CABG and 
left ventricular aneurysmectomy, 2; CABG and valve 
replacement, 11 (mitral 5, aortic 6); mitral valve replace- 
ment, 2; aortic valve replacement, 1; CABG and double 
valve replacement, 2; CABG and ventricular septal defect 
closure, 1; and postinfarction ventricular septal defect 
closure, 1. Because of an extremely unstable hemody- 
namic situation, the sternotomy could not be closed in 18 
patients (11 in the prophylaxis group and 7 in the control 
group; p = 0.283). Mean durations of IABP and open 
chest were 109.8 hours (SD 125.6 hours; minimum 6 
hours; maximum 840 hours) and 61.7 hours (SD 66.2 
hours; minimum 6 hours; maximum 288 hours), respec- 
tively, without a statistically significant difference between 
the two groups. During the study period 2.6% of the 
patients needed IABP support. 
Follow-up. The mean follow-up period among surviv- 
ing patients was 53.47 days (SD 99.7 days; minimum 3 
* SD = Standard eviation. 
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Table I. Type of infection 
Prophylaxis 
group Control group 
Type of p 
infection No. % No. % Value 
Pneumonia 9 32 13 52 NS 
Sepsis 5 18 3 12 NS 
Sternal wound 1 4 1 4 NS 
Total 15 17 NS 
NS, Not significant. 
Table II. Type of pathogen 
Prophylaxis Control 
group group p 
Type of organism (No.) (No.) Value 
Gram-negative 11 17 NS 
Gram-positive 9 15 NS 
Gram-negative + 7 12 NS 
gram-positive 
Multiple organisms (>2) 10 17 NS 
CNS 8 12 NS 
Candida 12 14 NS 
CNS, Coagulase-negative staphylococci; NS, not significant. 
days; maximum 540 days). Hospital deaths and late deaths 
were defined according to published guidelines of The 
American Association for Thoracic Surgery. 12
Statistical methods. We used Fisher's exact text o deter- 
mine significance for discrete variables. Continuous variables 
were analyzed by a Mann-Whitney test. The relative risk was 
calculated by the statistical program EPED. 13 
Results 
No patient in either group had to be excluded 
from the study. 
Early mortality. Total early mortality was 15 of 
53 patients (28.3%). In the prophylaxis group early 
mortality was 7 of 28 patients (25%) and in the 
control group 8 of 25 patients (32%). Differences 
between the two groups were not statistically signif- 
icant (t7 = 0.397). Death occurred in the early 
postoperative period after a mean interval of 8.3 
days. In the study group, cause of death was cardio- 
genic in 3 patients (low cardiac output, 2; arrhyth- 
mia, 1), related to sepsis with multiorgan failure in 3 
patients, and of cerebral origin in 1 patient. In the 
control group, the cause was low output in 5 and 
sepsis in 3 patients. 
Infections. Postoperative infections (Table I) oc- 
curred in 15 of 28 patients (53.6%) in the study 
group (95% confidence interval = 53.9% to 72.5%) 
and in 17 of 25 patients (68%) in the control group 
Table III. Isolated pathogens in patients with 




Serratia 1 1 
Proteus 1 2 
Enterobacter 3 1 
Haemophilus influenzae 2 5 
Klebsiella 1 3 
Pseudomonas 0 2 
Escherichia coli 0 2 
Citrobacter 0 1 
Enterococci 1 0 
Staphylococcus aureus 1 0 
Streptococcus pneumoniae 1 2 
Hemolytic streptococci 1 0 
(95% confidence interval 46.5% to 85.0%), without 
a statistically significant difference between groups 
(p = 0.265). The relative risk for infection was 1.27 
(95% confidence limits 0.82 to 1.97) and, measured 
by the odds ratio, 1.84 (95% confidence limits 0.53 
to 6.6) for the control group versus the study group. 
Sepsis occurred in 5 patients (18%) of the study 
group and in 3 patients (12%) of the control group 
(p = 0.708), with a relative risk of 0.93 (95% 
confidence interval 0.75 to 1.17) and an odds ratio of 
0.63 (95% confidence interval 0.09 to 3.71) for the 
control group versus the study group. The type of 
pathogens cultivated in both groups is indicated in 
Table II. The different pathogens i olated in tra- 
cheal or bronchial aspirations from patients with 
pneumonia re indicated in Table III. Gram-nega- 
tive organisms accounted for the majority of isolates 
in both groups. In all patients with sepsis, only CNS 
could be isolated from the bloodstream: in the 
prophylaxis group, 1 blood culture, 2 intravascular 
catheters, and 2 IABPs; in the control group, 1 
intravascular catheter and 2 IABPs. The following 
organisms could be isolated (prophylaxis group/ 
control group): blood culture: CNS, 2/3; Enter- 
obacter agglomerans, 0/1; Streptococcus mitis, 0/1; 
intravascular catheters: CNS, 7/8; Enterococcus, 2/0; 
Enterobacter cloacae, 0/1; Serratia, 0/1; IABPs: CNS, 
5/3. In the prophylaxis group growth of CNS was 
found on all culture-positive IABPs (5/5) and on 7 of 
8 culture-positive intravascular catheters. In the 
control group CNS was found on all culture-positive 
intravascular catheters (8/8) and IABPs (3/3). Can- 
dida was found in bacteriologic cultures in 12 pa- 
tients of the prophylaxis group (43%) and in 14 
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patients of the control group (56%). Tracheal secre- 
tion was responsible for 88% of all positive cultures. 
Antibiotic therapy. Because of new-onset infec- 
tion or changes of floral composition or resistance 
spectrum, antibiotic therapy was instituted in 15 of 
28 patients (14 combination therapies, 1single-drug 
therapy) in the prophylaxis group and in 20 of 25 
patients (19 combination therapies, 1 single-drug 
therapy) in the control group (p = 0.08). 
Laboratory data. Laboratory data and results of 
bacteriologic tests are depicted in Tables IV and V. 
The minimum body temperature was significantly 
lower in the control group (p = 0.019), and the 
minimum platelet count was also lower in the con- 
trol group (p = 0.030). The other laboratory values 
did not differ significantly between groups. Serum 
levels of vancomycin were measured in 13 patients: 
mean value for the peak level was 28.6 p~g/ml (SD, 
3.0 /xg/ml; minimum, 13.3 /xg/ml; maximum, 50.4 
/xg/ml) and for the trough level 8.2/xg/ml (SD, 6.0 
txg/ml; minimum, 3.8/xg/ml; maximum, 26.0 pog/ml). 
In both groups a total of 1158 bacteriologic tests 
were performed (blood cultures, 389; intravascular 
catheters, 208; tracheal secretions, 411; tips of 
IABPs, 42; wound swabs, 108). The number of 
microbiologic tests with (positive) or without (neg- 
ative) bacterial growth did not differ significantly in 
the two groups (Table V). There was also no 
significant difference in the number of patients with 
positive or negative bacteriologic results (Table VI). 
Discussion 
In this prospective, randomized study including 
only a high-risk group of patients having cardiac 
operations (low cardiac output, IABP), infectious 
outcome could not be effectively influenced by a 
postoperatively prolonged regimen of antibiotic pro- 
phylaxis compared with normal short-term prophy- 
laxis. For a number of reasons the study patients 
were at increased risk for infections: With the 
percutaneously implanted IABP and the intraarte- 
rial pump line, a large amount of intravascular 
foreign material remained in place, usually for a 
long time. The interruption of the skin barrier by 
percutaneously implanted evices and catheters may 
predispose to local infection at the site of entry or 
exit. Common skin pathogens like CNS or Staphy- 
lococcus aureus may colonize along the catheter 
tract, producing thrombophlebitis and sepsis. 14 
Staphylococcus epidermidis is most frequently re- 
sponsible for infections around foreign material. 
Nosocomial bacteremias are mostly caused by CNS 
Table IV. Laboratory parameters 
Prophylaxis Control 
group group 
Mean Mean p 
Laboratotyparameters value +_SD value +-SD Value 
Hematocrit (%), Min. 29.5 3.2 29.1 3.1 NS 
WBC (×103), Max. 15.3 7.4 15.4 7.4 NS 
WBC diff., Max. 47.2 10.9 44.4 14.8 NS 
Platelets (× 103) 
Max. 154.5 64.2 173.0 133.5 NS 
Min. 75.4 31 .9  60.1  23.0  0.06 
Phosphate (mmol/L) 
Max. 1.22 0.47 1.29 0.51 NS 
Min. 0.53 0 .48  0 .59  0.28 NS 
CRP (mg/L) 
Max. 227.3 98.8 205.3 81.3 NS 
Min. 58.9 35.0 68.1 46.1 NS 
Creatinine (b~mol/L) 
Max. 231 121 230 117 
Min. 121 39 137 64 NS 
Creat. clearance (ml/min) 61 42 45.4 34 NS 
Temperature (°C) 
Max. 38.5 0.8 38.1 1.1 NS 
Min. 36.9 1.0 36.5 0.7 0.019 
Minimum (Min.) and maximum (Max.) values are indicated. Creat. clear- 
ance, Creatinine clearance; CRP, c-reactive protein; SD, standard evia- 
tion; NS, not significant; WBC diff white blood cell differentiation. 
and have a mortality of up to 30%. 15-17 In addition, 
a prolonged period of low cardiac output can also be 
detrimental to the immune system. Hillis and asso- 
ciates  reported a 27% incidence of infection in a 
subgroup of patients with low cardiac output and 
prolonged antibiotic prophylaxis compared with an 
incidence of 3.5% to 5.1% in patients without low 
output. Additionally, closure of the thorax and 
tracheal extubation are often delayed in patients 
receiving inotropic and IABP support, and their stay 
in the intensive care unit is extended. The prolonged 
prophylaxis was performed with low-dose vanco- 
mycin and ticarcillin/clavulanate. Vancomycin is 
the prefered antibiotic against methicillin-resistant 
staphylococci, is-2° In our hospital the rate of methi- 
cillin resistance is 3% for Staphylococcus aureus and 
40% for CNS. 21 The sensitivity of both pathogens to 
vancomycin is 100%. With the low dosage, adverse 
effects of vancomycin, especially renal toxicity and 
hemodynamic impairment, 22' 23 are minimized. In a 
prospective study, Karp and Dick 24 demonstrated 
the efficacy of low-dose vancomycin (500 mg twice 
daily) in the prevention of breakthrough gram- 
positive infections in patients with aplastic leukemia. 
In the presented study, all patients with prolonged 
prophylaxis had low-dose vancomycin during a vari- 
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Table V. Bacteriology: Number of microbiologic tests showing bacterial growth 
Bacteriology No, Positive % Prophylaxis group Control group p Value 
Blood 389 12 3.0 Pos. 5 Pos. 7 NS 
Neg. 204 Neg. 173 
208 28 13.5 Pos. 13 Pos. 15 NS 
Neg. 98 Neg. 82 
411 265 64.5 Pos. 142 Pos. 123 NS 
Neg. 101 Neg. 45 
42 8 19 Pos. 5 Pos. 3 NS 
Neg. 17 Neg. 17 
108 9 8.3 Pos. 2 Pos. 7 NS 
Neg. 67 Neg. 32 
1158 322 27.8 Pos. 167 Pos. 155 NS 








/ABP, Intraaortic balloon pump; NS, not significant. 
Table VI. Number of patients with positive or negative bacteriologic results 
Cultured Prophylaxis Control 
material Bacteriology No. of patients group group p Value 
Blood Positive 7 2 5 NS 
Negative 40 24 16 
Intravascular Positive 16 8 8 NS 
catheters Negative 27 14 13 
Tracheal Positive 43 22 21 NS 
secretion Negative 7 6 1 
IABP Positive 8 5 3 NS 
Negative 33 17 16 
Wound Positive 6 2 4 NS 
Negative 15 10 5 
/ABP, Intraaortic balloon pump; NS, not significant. 
able length of time (duration of IABP); the therapy 
was principally aimed at reducing catheter-related 
gram-positive infections. The trough serum levels 
were measured in 13 patients and they were well 
above 2 /xg/ml (minimum, 3.8 /xg/ml) in all cases. 
Ticarcillin, on the other hand, is active against 
/3-1actamase-producing strains of Staphylococcus 
aureus, Escherichia coli, Klebsiella sp., Proteus, Hae- 
mophilus inftuenzae, and Pseudomonas p. and 
against anaerobes. 2s 
The infection rate in our series was higher in the 
patient group without prolonged prophylaxis, but 
the difference was not statistically significant (p = 
0.265). The rate of sepsis was higher in the prophy- 
laxis group. In a worst-case situation, assuming a
relative risk of 1.97 (upper 95% confidence limit) for 
infection and a relative risk of 1.17 (upper 95% 
confidence limit) for sepsis, a clear benefit of pro- 
longed prophylaxis cannot be found. Pneumonia 
diagnosed with the use of clinical and radiologic 
criteria occurred less frequently in the prophylaxis 
group. The differences were not significant. In pa- 
tients with pneumonia, gram-positive cocci could be 
isolated only in the group with vancomycin/ticarcil- 
lin prophylaxis, whereas in all remaining patients of 
both groups the isolates were gram negative. Pneu- 
monia in most patients was diagnosed after 48 hours 
when ticarcillin was discontinued. With vancomycin 
alone a reduction of gram-negative r spiratory tract 
infections could not be expected. In patients with 
clinical sepsis, CNS was the most prevalent organ- 
ism in both groups, and it could be detected in blood 
cultures (n = 2), on intravascular catheters (n = 2), 
and on IABPs (n = 2) in the prophylaxis group. In 
contrast o the observations of Karp and Dick, z4 
low-dose vancomycin i  our series could not reduce 
colonization of IABP and intravascular catheters 
with CNS, the main organism vancomycin was di- 
rected against. A wound infection occurred in a 
single patient in both groups with Escherichia coli in 
the prophylaxis group and CNS in the control group. 
The rate of wound infection is too low, however, to 
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allow us to draw any conclusions. The whole spec- 
trum of isolated organisms did not show a significant 
difference in either group. 
Total mortality was 28% and was similar in the 
two groups. Sepsis and multiorgan failure were the 
only infectious causes of death in three patients of 
each group. 
Antibiotics had to be instituted in more patients 
of the control group than the prophylaxis group. The 
difference, however, was small and insignificant (p = 
0.08). It may partly be due to the fact that the study 
was unblinded and the threshold for starting antibi- 
otics was lower in the patient group without ongoing 
prophylaxis. When comparing the number of posi- 
tive bacteriologic ultures and the number of pa- 
tients with positive bacteriologic ultures, the two 
groups did not differ significantly. Additionally, all 
laboratory data measuring parameters uggesting 
infection were similar. The mean minimal body 
temperature was the only parameter that was signif- 
icantly different and lower in the control group. This 
difference, however, may be of no clinical signifi- 
cance. Candidiasis is a known complication of 
broad-spectrum antibiotics, intravascular catheters, 
and hyperalimentation. 26-28 In almost every patient 
in the present series, these three risk factors were 
present. However, candidiasis was found more often 
in the control group, but not significantly more often 
than in the experimental group. Nevertheless, 73% 
of all patients with positive Candida cultures had 
additional antibiotic therapy for 7 to 10 days. As 
reported by Hillis and coworkers, a candidiasis may 
become more frequent when the duration of antibi- 
otic administration is prolonged. Vancomycin or 
ticarcillin did not show any side effects of clinical 
relevance. 
The size of the studied population is small and 
limits the strength of the conclusions. Estimating the 
number of patients necessary to reach a solid con- 
clusion, however, seemed too speculative in view of 
the variability of the incidence of infections in this 
inhomogeneous and variable high-risk group of pa- 
tients. 
In conclusion, we could demonstrate that an 
additional and prolonged postoperative Period of 
broad-spectrum prophylaxis with low-dose vanco- 
mycin and ticarcillin/clavulanate could not effec- 
tively influence infectious outcome in a high-risk 
group of patients undergoing cardiac operations. 
Low-dose vancomycin did not reduce the rate of 
infections or the colonization of intravascular cath- 
eters with gram-positive organisms. 
We acknowledge the assistance of Burkhardt Seifert 
(statistical consultant) in manuscript preparation. 
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